ATE413188T1 - Menschliche papillomavirus impfstoff- formulierungen - Google Patents

Menschliche papillomavirus impfstoff- formulierungen

Info

Publication number
ATE413188T1
ATE413188T1 AT00905886T AT00905886T ATE413188T1 AT E413188 T1 ATE413188 T1 AT E413188T1 AT 00905886 T AT00905886 T AT 00905886T AT 00905886 T AT00905886 T AT 00905886T AT E413188 T1 ATE413188 T1 AT E413188T1
Authority
AT
Austria
Prior art keywords
human papillomavirus
vaccine formulations
papillomavirus vaccine
formulations
human
Prior art date
Application number
AT00905886T
Other languages
English (en)
Inventor
David Volkin
Li Shi
Henryk Mach
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE413188T1 publication Critical patent/ATE413188T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT00905886T 1999-02-05 2000-02-01 Menschliche papillomavirus impfstoff- formulierungen ATE413188T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11872399P 1999-02-05 1999-02-05

Publications (1)

Publication Number Publication Date
ATE413188T1 true ATE413188T1 (de) 2008-11-15

Family

ID=22380362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905886T ATE413188T1 (de) 1999-02-05 2000-02-01 Menschliche papillomavirus impfstoff- formulierungen

Country Status (15)

Country Link
US (1) US6251678B1 (de)
EP (1) EP1150712B1 (de)
JP (2) JP4841726B2 (de)
KR (1) KR20010093290A (de)
AR (1) AR022510A1 (de)
AT (1) ATE413188T1 (de)
AU (1) AU764138B2 (de)
CA (1) CA2361837C (de)
CY (1) CY1108702T1 (de)
DE (1) DE60040727D1 (de)
DK (1) DK1150712T3 (de)
ES (1) ES2313881T3 (de)
PT (1) PT1150712E (de)
SI (1) SI1150712T1 (de)
WO (1) WO2000045841A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA982950B (en) * 1997-04-08 1998-10-19 Merck & Co Inc Stabilized human papillomavirus formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
AU2001277781A1 (en) * 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
CA2327950A1 (en) * 2000-12-08 2002-06-08 Groupe Minutia Inc. Grain refining agent for cast aluminum or magnesium products
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003061708A1 (en) * 2002-01-18 2003-07-31 Schering Aktiengesellschaft Stabilized formulations of adenovirus
WO2003068993A1 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
TWI349557B (en) * 2002-12-20 2011-10-01 Glaxosmithkline Biolog Sa Use of hpv 16 and hpv 18 vlps for vaccine preparation
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
CA2551896A1 (en) 2003-12-30 2005-07-21 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
RU2417793C2 (ru) * 2004-10-05 2011-05-10 Цитос Биотехнологи Аг Конъюгаты впч-антиген и их применение в качестве вакцин
EP1812051A2 (de) * 2004-10-05 2007-08-01 Cytos Biotechnology AG Vlp-antigen-konjugate und ihre verwendung als vakzine
JP4182074B2 (ja) * 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
JP2008531722A (ja) 2005-03-04 2008-08-14 ダイナバックス テクノロジーズ コーポレイション 構造的に安定なコンジュゲート分子を含む組成物
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2008042789A1 (en) 2006-09-29 2008-04-10 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
US20090047255A1 (en) * 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
US9439958B2 (en) * 2009-12-23 2016-09-13 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
EP3246044B2 (de) 2010-08-23 2024-04-10 Wyeth LLC Stabile formulierungen von neisseria-meningitidis-rlp2086-antigenen
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
WO2012038801A1 (en) 2010-09-21 2012-03-29 National Institute Of Immunology A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
WO2012177970A1 (en) * 2011-06-24 2012-12-27 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CN108567975A (zh) * 2011-07-11 2018-09-25 武田疫苗股份有限公司 胃肠外诺如病毒疫苗配制剂
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
EP3246400B1 (de) 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Aufreinigung von herpesvirus
WO2013132452A2 (en) 2012-03-09 2013-09-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US11260123B2 (en) * 2012-05-21 2022-03-01 Sanofi Pasteur Limited Herpesvirus compositions and related methods
WO2013191225A1 (ja) 2012-06-20 2013-12-27 国立大学法人 東京大学 粘膜免疫賦活化剤及びｈｐｖ感染症治療用経口医薬組成物
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
AU2013370928B2 (en) * 2012-12-28 2019-05-02 Qiagen Sciences Llc A cell mediated immune response assay
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
US9254332B2 (en) 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
CN104479892A (zh) * 2014-11-06 2015-04-01 王越 一种具有植物杀菌功能洗衣液的制备方法
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US12508279B2 (en) 2016-04-01 2025-12-30 Colorado State University Research Foundation Compositions and methods for enhancing innate immunity in a subject for treatment of infections and cancer and other acute and chronic conditions of the eye
WO2017173371A1 (en) * 2016-04-01 2017-10-05 Colorado State University Research Foundation Compositions and methods for enhanced innate immunity
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
CA3079828A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
CN112439059B (zh) * 2019-09-02 2022-02-08 怡道生物科技(苏州)有限公司 重组人乳头瘤病毒疫苗组合物及其用途
BR112022004921A2 (pt) 2019-09-27 2022-07-19 Pfizer Composições para neisseria meningitidis e métodos das mesmas
JP2026000483A (ja) * 2022-11-22 2026-01-06 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン
WO2025216920A1 (en) * 2024-04-08 2025-10-16 The Government Of The United States, As Represented By The Secretary Of The Army Freezable aqueous aluminum salt adjuvants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
CA2189882C (en) * 1994-05-16 2005-09-20 Kathrin U. Jansen Papillomavirus vaccines
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
ATE377428T1 (de) * 1996-09-26 2007-11-15 Merck & Co Inc Rotavirus-impfstoff
ATE470434T1 (de) * 1997-02-06 2010-06-15 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
PT973546E (pt) * 1997-04-08 2004-06-30 Merck & Co Inc Formulacoes estabilizadas de virus de papiloma humano

Also Published As

Publication number Publication date
CA2361837C (en) 2011-06-07
US6251678B1 (en) 2001-06-26
DE60040727D1 (de) 2008-12-18
JP4841726B2 (ja) 2011-12-21
DK1150712T3 (da) 2009-02-02
ES2313881T3 (es) 2009-03-16
EP1150712A2 (de) 2001-11-07
JP2002536340A (ja) 2002-10-29
JP2011225578A (ja) 2011-11-10
AU764138B2 (en) 2003-08-14
CA2361837A1 (en) 2000-08-10
CY1108702T1 (el) 2013-09-04
WO2000045841A2 (en) 2000-08-10
AR022510A1 (es) 2002-09-04
AU2749200A (en) 2000-08-25
PT1150712E (pt) 2008-12-22
SI1150712T1 (sl) 2009-02-28
KR20010093290A (ko) 2001-10-27
EP1150712B1 (de) 2008-11-05
WO2000045841A3 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
ATE413188T1 (de) Menschliche papillomavirus impfstoff- formulierungen
DK1210113T3 (da) Kombinerede vaccinepræparater
NO20014323L (no) Vaksine
DE60045324D1 (de) Impfstoffzusammensetzung
LU91328I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)
NO2010011I1 (no) Levende svekket humant rotavirus stamme Rix 4414 (Rotavirus vaksine)
DK1031346T3 (da) Ikke-invasiv vaccination gennem huden
NO20030713L (no) Oral faststoffdose vaksine
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20031597L (no) Medisinske aerosolformuleringer
NO20015670L (no) Forbedrede farmasöytiske formuleringer
IS6398A (is) Lyfjablöndur
EP1565583A4 (de) Hiv-vakzine-formulierungen
ATE392214T1 (de) Impfstoff gegen geschlechtlich übertragene krankheiten
HUP0202770A3 (en) Human papilloma virus vaccine
GB9911823D0 (en) New vaccine formulations
GB9911825D0 (en) New vaccine formulations
GB9911824D0 (en) New vaccine formulations
ITMI992410A0 (it) Vaccino per hiv
GB0008029D0 (en) New vaccine formulations
NO20002213L (no) Babesia vaksine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1150712

Country of ref document: EP

EEFA Change of the company name